Study of Serum Magnesium Level in Type 2 Diabetes Mellitus by Subash Chandra Bose, G
 STUDY OF SERUM MAGNESIUM LEVEL 
IN TYPE 2 DIABETES MELLITUS 
 
Dissertation submitted in partial fulfilment of requirements for 
 
M.D.DEGREE IN GENERAL MEDICINE 
 
BRANCH I 
 
Of 
 
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY, 
CHENNAI, INDIA. 
 
   
 
THANJAVUR MEDICAL COLLEGE , 
THANJAVUR - 613004. 
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY, 
CHENNAI-600032. 
APRIL 2013 
 
 
 CERTIFICATE 
 
 This is to certify that the dissertation entitled “STUDY OF SERUM 
MAGNESIUM LEVEL IN TYPE 2 DIABETES MELLITUS” is a bonafide 
work done by Dr.SUBASH CHANDRABOSE G. at Thanjavur Medical 
College,Thanjavur in partial fulfilment of the university rules and regulations 
for award of M.D., Degree in General Medicine (Branch-I) under my guidance 
and supervision during the academic year 2010-2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prof.Dr.C.GUNASEKARAN M.D.D.C.H, 
The Dean I/C, 
Thanjavur Medical College, 
Thanjavur–613004. 
 
 
 
 
 
 
Prof.Dr.S.MUTHUKUMARAN,M.D., 
Head of the Department, 
Department of Internal Medicine, 
Thanjavur Medical College, 
Thanjavur–613004. 
 
 
 
 
Prof.Dr.K.NAGARAJAN,M.D., 
Unit Chief M-III, 
Department of Internal Medicine, 
Thanjavur Medical College, 
Thanjavur–613004. 
DECLARATION 
 I solemnly declare that the dissertation titled “STUDY OF SERUM 
MAGNESIUM LEVEL IN TYPE 2 DIABETES MELLITUS” is done by 
me at Thanjavur Medical College, Thanjavur during 2010-2013 under the 
guidance and supervision of Prof. Dr.K.NAGARAJAN,M.D., The dissertation 
is submitted to The Tamilnadu Dr.M.G.R. Medical University towards the 
partial fulfilment of requirements for the award of M.D. degree in General 
Medicine (Branch Ι). 
 
 
 
 
Place: Thanjavur                                         Signature of candidate 
Date:                                  ( DR.G.SUBASH CHANDRABOSE ) 
 
  
ACKNOWLEDGEMENT 
 At the outset, I thank Prof. Dr.C.GUNASEKARAN M.D.D.C.H,  
The Dean I/C, Thanjavur Medical College and Hospital, Thanjavur for granting 
me permission to do my dissertation and for allowing me to use institutional 
facilities. 
 I am grateful to Prof. Dr.S.MUTHUKUMARAN M.D., Professor and 
Head, Department of Internal Medicine, Thanjavur medical college and 
Hospital for his constant support and guidance throughout my Post graduate 
period and during the course of this study. 
 I am indebted to Prof. Dr.K.NAGARAJAN M.D., Professor of 
Medicine and my unit chief, who constantly helped me and guided me in this 
study and during my post-graduate period. 
 I profoundly express my heartiest thanks to my respected Professors  
Prof. Dr.P.G.SANKARANARAYANAN M.D, Prof. Dr.S.MANOHARAN 
M.D, Prof. Dr C.GANESAN M.D, and Prof. Dr.D.NEHRU M.D. D.M.R.D, 
for their advice,  guidance and valuable criticism which enabled me to do this 
work effectively. 
 I would also like to thank  Prof. Dr.M.THANGARAJ M.D.D.M, Head 
of Department of Neurology, Department of Neurology, Thanjavur Medical 
College and Hospital, Thanjavur who supported and helped me during this 
study. 
 I would also like to thank Assistant Professors Dr.S.ELANGOVAN 
M.D.D.M, Dr. K.BALAMURALI M.D.D.M, Department of Neurology, 
Thanjavur Medical College and Hospital, Thanjavur for their encouragement  
during this study. 
  I would also like to thank Dr. C. PARANTHAGAN M.D. Registrar, 
Department of Internal Medicine for his support and guidance. 
 I would also like to thank Dr.J.VIJAYBABU M.D.D.M.,. 
Dr.S.VETRIVEL M.D., and Dr. THIRUMURUGAN M.D., Assistant 
Professors of my unit, Department of Internal Medicine for their constant help, 
encouragement and support throughout this study and during my post graduate 
period.  
 I would also like to thank J.S.JESUS RAJA M.E, for his excellent 
support in statistical analysis. 
 I express my sincere gratitude to all the patients who participated in the 
study. 
 Lastly, I thank all my professional colleagues for their support and 
valuable criticism. 
 
 
 
CONTENTS 
 
 
 
SL.NO TITLE PAGE NO 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 METHODOLOGY 53 
5  RESULTS 58 
6 DISCUSSION 80 
7 CONCLUSION 86 
8 ANNEXURES 
 
 BIBLIOGRAPHY  
 ANNEXURE I -ABBREVIATIONS 
 
 ANNEXURE II- PROFORMA 
 
 ANNEXURE III-MASTER CHART 
 
 ANNEXURE IV- KEYS TO MASTER CHART  
 ANNEXURE V- CONSENT FORM  
STUDY OF SERUM MAGNESIUM LEVEL IN TYPE 2 
DIABETES MELLITUS 
ABSTRACT  
BACKGROUND 
 A high prevalence of magnesium deficiency is reported in diabetics. 
Magnesium depletion has a negative impact on glucose homeostasis and insulin 
sensitivity in type 2 diabetic patients as well as on the evolution of 
complications such as retinopathy, nephropathy, neuropathy and arterial 
atherosclerosis. The aim of this study is to estimate the prevalence of 
hypomagnesemia in patients with type 2 diabetes mellitus and its correlations 
with microvascular complications of diabetes like retinopathy, nephropathy, 
neuropathy. 
MATERIALS AND METHODS: 
  Patients with type 2 diabetes admitted in Thanjavur Medical College and 
Hospital over a period of one year between October 2011 to October 2012 
formed the study population. The sample size was 100 patients. Serum 
magnesium concentration was measured by calmagite dye method. 
RESULTS: 
The study revealed that prevalence of hypomagnesemia in study subjects 
was 35%. Sex, age and duration of diabetes were not significant predictors of 
serum magnesium. Significant association was found between hypomagnesemia 
and diabetic retinopathy, nephropathy, neuropathy. Significant correlations were 
not found with co morbidities such as ischemic heart disease and hypertension.  
Low serum magnesium concentrations are common in type 2 diabetics. 
Magnesium deficiency is conclusively associated with diabetic retinopathy, 
nephropathy, neuropathy.  
KEY WORDS: 
Magnesium ,Diabetes Mellitus, Retinopathy, Nephropathy, Neuropathy 
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INTRODUCTION 
 
 
India is frequently referred to as the diabetic capital of the world as it has 
the highest number of cases in the world. 
In worldwide the last 2 decades, incidence is suddenly increased from 30 
million cases in 1985 to 171 million in 2000. Recent data suggests that 
prevalence of DM by the year 2030 could be 360 million.   DM is worldwide in 
distribution and the incidence of both types is rising.
1, 2
 
The distribution of both T1 DM and T2DM varies worldwide, due to 
relative difference in genetic and environmental  factors in different parts of the 
world. Recent data shows it is associated with 10-30% reduction of life 
expectancy, most common cause of blindness in the age group of 20 to 65 years,  
25 fold increased risk of non traumatic lower limb amputations and increase 
incidence of end stage renal disease approximately 1000 patients per year
2
. 
 India had around 31.7 million cases in year 2000 which is expected to 
rise alarmingly to around 79.4 million in 2030 by which time every fifth 
diabetic subject in the world would be an Indian
3
.  
In Tamilnadu the prevalence in 2008 is 18.6% in urban areas and 9.1% in 
rural areas
3
. 
Although DM can cause hypomagnesemia , low serum magnesium level 
is a risk factor for DM. Magnesium is an essential element  for several enzymes 
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that play important role in glucose metabolism. Animal studies found that low 
magnesium has a negative effect on post receptor signalling of insulin. Some 
studies have also found that magnesium supplementation improves insulin 
action and glucose metabolism
 
in diabetics
4
. 
Magnesium is involved in multiple levels of insulin secretion. 
Magnesium deficiency can modify the Na
+
 K
+
 ATPase channel that maintains  
sodium, potassium and glucose transport
5
. 
In DM there is a direct correlation between serum magnesium 
concentration in blood and cellular glucose disposal that is independent of 
insulin secretion.
6
  
Low serum magnesium level has direct correlation with microvascular 
complications (retinopathy
7
, neuropathy. nephropathy) and macrovascular 
complications (IHD and cerebrovascular disease)
8
. 
In elderly type2 DM Paolisso hypothesized that oral magnesium 
supplementation for 4 weeks results in decreased fasting blood sugar level 
increased plasma and RBC magnesium level.
9
 
In this study serum magnesium concentration in type2 DM patients is 
correlated with occurrence of microvascular complications. 
  
3 
 
 
OBJECTIVES 
 
The aims of this study are 
1. Measurement of serum magnesium concentration in diabetes mellitus . 
2. To estimate the prevalence of hypomagnesemia in patients with type 2 
diabetes mellitus  
3.  Its correlation with microvascular complications  like retinopathy, 
nephropathy, neuropathy. 
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REVIEW OF LITERATURE 
 
DIABETES MELLITUS  
Diabetes Mellitus is a clinical syndrome characterized by high blood 
sugar level (hyperglycemia) and glycosuria due to relative or absolute 
deficiency of insulin secretion or its action, or insulin resistance that leads to 
disturbances in carbohydrate ,protein, fat metabolism , water and electrolyte 
homeostasis. 
 
THE HISTORICAL ASPECTS 
Its history has been characterized by numerous cycles of discovery, 
neglect and rediscovery. Its history may be divided into four major periods. The 
„ANCIENT‟ period showed the first clinical features of DM and its 
complications. The 16
 th
 to 18
th
 
 centuries have been termed the „DIAGNOSTIC‟ 
period, as DM was then identified as a separate disease entity. The mid to late 
19
th
 centuries may be consider as the first „EXPERIMENTAL‟ period.  During 
this period role of the pancreas became clear and the molecular level of diabetes 
were initially identified
10
. Finally, in the 20
th 
century knowledge about diabetes 
is well known.  
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The word Diabetes in Greek means – “I run through Siphon”.  Indian 
name for Diabetes is Madhumeha – Honey in rain. In 16th century, Susrutha in 
the Sanskirit book of surgery, and Charaka in the Sanskirit book of medicine 
have mentioned about Diabetes. The first person -Vaidys – tested the urine of 
diabetic patients. 
SPECTRUM OF DIABETES MELLITUS & GLUCOSE HOMEOSTASIS 
 
 
Types 
Normal 
glucose 
tolerance 
(mg/dl) 
                           HYPERGLYCEMIA 
PREDIABETES 
IFG 
& 
IGT 
(mg/dl) 
DIABETES MELLITUS 
 
NOT 
INSULIN 
REQUIRED 
INSULIN 
REQUIRED 
FOR 
CONTROL 
INSULIN 
REQUIRED 
FOR 
SURVIVAL 
T1DM 
 
T2DM  
 
Other  types 
  
GDM  
 
Time 
(years)  
 
   
FBG 
(mg/dl)  
2-h PPBG 
(mg/dl)  
< 110  
< 140  
110-125  
140 – 199  
≥ 126  
≥ 200  
 
 
 ETIOLOGICAL CLASSIFICATION OF DIABETES  
1. Type 1 Diabetes 
2. Type 2 Diabetes  
3. Specific types  
4. Gestational Diabetes Mellitus (GDM) 
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SPECIFIC TYPES OF DIABETES 
A. Genetic mutation in the β-cell function:  
1. MODY - maturity onset diabetes of the young 
 Type1- Hepatocyte nuclear transcription factor 4α. 
 Type2 -Glucokinase.  
Type 3 -HNF 1α . 
Type 4- Insulin promoter factor 1. 
 Type5- HNF 1β. 
Type 6- Neuro D1. 
2. Mitochondrial DNA  
3. Proinsulin or insulin conversion  
 
B. Genetic mutations in insulin action:  
1. Lipodystrophy syndromes 
2. Leprechaunism syndrome  
3. Rabson-Mendenhall syndrome 
4. Type A insulin resistance 
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C. Diseases of the pancreas: 
It includes pancreatitis, pancreatectomy, pancreatic malignancy, cystic 
fibrosis, etc. 
D. Endocrine disorders:  
 Pheochromocytoma, somatostatinoma, aldosteronoma, etc. 
E. Drugs:  
Glucocorticoids, diazoxide, beta agonists, thiazide diuretics.  
F. Infectious causes: 
Rubella, cytomegalovirus, coxsackie virus.  
G. Immune-mediated Diabetes:  
Stiff-man syndrome and  anti-insulin receptor antibodies.  
H. Genetic syndromes  
Myotonic dystrophy, porphyria, Prader-Willi syndrome. , Klinefelter‟s, Turner‟s  
and Down‟s syndrome. 
GESTATIONAL DIABETES MELLITUS (GDM)
11 
It is the occurrence of reduced glucose tolerance during gestation. 
Incidence: 7% (range 2–10%) of pregnancies. 
Most women revert to normal euglycemia in postpartum period, but have a 
subsequent risk (35–60%) of developing diabetes mellitus in the next 10–20 
years. 
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Effects of diabetes on pregnancy: 
 Hydraminos 
 Toxaemia of pregnancy 
 Maternal infections 
 Difficult labour 
 Recurrent abortions  
 Postpartum haemorrhage  
 Puerperal sepsis. 
Effects of diabetes on the foetus: 
 Prematurity 
 Still birth 
 Macrosomia  
 Postpartum hypoglycaemia  
 Respiratory distress syndrome  
 Hyperbilirubinemia 
 Congenital heart disease  
 Neural tube defects. 
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TYPE 1 DIABETES MELLITUS 
 
Pathogenesis Of Type 1 Diabetes Mellitus: 
 
     Normal islet 
 
    
   ?Viral infection in pancreatic beta cell 
    
 
   Secretion of IFN-α by pancreatic beta cell 
 
 
 
  Hyperexpression of MHC class1 antigen within beta cell 
 
 
 
           Insulitis 
 
     
    Insulin deficient islets 
 
 
 
 
Immune Mediated Diabetes (Type 1A)  
Its incidence is around 5-10% all diabetes. It occurs due to immune 
mediated destruction of pancreas. 
Pathogenesis: 
1. Genetic predisposition: Diabetogenic genes are located in short arm of 
chromosome 6 
2. Environmental triggers 
a) Viral infections like rubella virus, CMV, mumps virus, etc. 
b) Toxins like pentamidine, streptozocin 
10 
 
Viruses and above agents directly act on beta cells and initiate autoimmune 
processes against these cells. 
3.  Immune mechanism 
DM can occur with other autoimmune disorders. It is due to presence of 
diabetogenic peptide which triggers the immune system. .Antibodies against β-
cells include  
1. Islet cell auto antibodies,  
2. Autoantibodies to insulin,  
3. Autoantibodies to glutamic acid decarboxylase (GAD65) and  
4. Autoantibodies to tyrosine phosphatases IA-2 and IA-2B. 
Anyone of above auto antibodies  present in 85-90% of patients. 
Age of onset is usually less than 30 years. Usually associated with 
prominent muscle wasting. It has an abrupt onset with rapid progression course. 
Classical symptoms of diabetes like polyuria, polyphagia, polydipsia are present. 
Family history of diabetes mellitus is usually absent. 
HLA DR3 or DR4 seen in>90% of patients. Pancreatic islet cells (of 
langerhans) almost destroyed and plasma insulin is low to absent. Plasma C 
peptide level is low. It is usually associated with other autoimmune diseases. 
Acute complications like diabetic ketoacidosis are very common. Insulin 
therapy is needed for survival and mortality is higher in untreated patients. 
  
11 
 
 
Idiopathic Diabetes (Type 1B)  
These persons have absolute deficiency of insulin and are at risk  of 
developing   ketoacidosis. It is strongly inherited and there is no evidence for 
antibodies to beta cells. It is not associated with HLA. 
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TYPE2 DIABETES MELLITUS 
90-95% of diabetics are Type 2 DM. Patients have insulin resistance and 
have relative deficiency of insulin. Specific aetiologies are not known. It usually 
starts after the age of 30 years. It has insidious onset, with gradual progressive 
course. Polyuria, polyphagia, polydipsia are not so classically seen as in type 1 
DM. Family history of diabetes mellitus is usually present. No HLA links are 
seen. 50% concordance is seen in identical twins. Pancreatic islet cells are not 
totally destroyed .Plasma insulin in serum normal to high. Complications like 
hyperosmolar hyperglycaemic non ketotic coma are very often seen. 
Risk of developing T2DM: 
Age of onset of T2DM in proband 
(years) 
Age corrected risk of T2DM for 
Siblings(%) 
25-44 53 
45-54 37 
55-64 38 
65-80 31 
 
Pathogenesis of Type 2 DM: 
1) Insulin Resistance 
2) Pancreatic Beta Cell Failure 
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Insulin resistance: 
Exact cause of insulin resistance is unknown. Possible mechanism  is 
increase release of free fatty acids from adipose tissue that induce insulin 
resistance. In addition there is increased release of adipokines which act on 
receptors of insulin and dampen the action of insulin. There is a higher 
prevalence of insulin resistance is seen in metabolic syndrome. 
Pancreatic Beta cell failure: 
In the earlier stage of diabetes mellitus only moderate reduction of insulin 
secreting beta cells lost. At the time of diagnosis of type 2 DM more than 50% 
reduction of beta cell is seen. Most important pathological feature is the 
deposition of amyloid in pancreatic cells. There is no change in alpha cells but 
progressive destruction of beta cells leads to development of hyperglycemia. 
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Differences between Type 1 and Type 2 Diabetes Mellitus: 
 T1DM T2DM 
Age of onset(years) Less than 40 More than 50 
Duration of symptoms Usually weeks Months to years 
weight Normal or decrease Obese 
Ketone bodies in urine Present Absent 
Insulin requirement for 
survival 
Needed Not needed 
Auto antibodies Present Not present 
Diabetic complications at 
the time of presentation 
Not present Present 
Family history Uncommon Seen in 25% 
Other autoimmune 
disorders 
common Uncommon 
 
Clinical features of DM 
 Polyuria 
 Increased thirst 
 Dry mouth 
 Nocturia 
 Tiredness, lethargy, fatigability 
 Visual defect 
15 
 
 Excessive weight loss 
 Nausea, vomiting, headache 
 Polyphagia 
 Genital candidiasis 
 Mood changes, irritability 
Diagnostic criteria for Diabetes mellitus 
It includes 
A. Symptoms of diabetes plus random blood sugar ≥ 200 mg/dl 
B. Fasting plasma sugar ≥ 126 mg/dl 
C.2 hour postload plasma sugar ≥ 200 mg/dl during an oral GTT 
D.HbA1C >6.5% 
 
The new Diagnostic criteria for pre-diabetes and diabetes mellitus 
FBS > 100 mg/dl = normal fasting glucose 
FBS ≥100 mg/dl and <126 mg/dl =impaired fasting glucose (IFG) 
FBS ≥ 126 mg/dl = provisional diagnosis of diabetes (on more than one 
occasion) 
The corresponding categories when the oral GTT is used ,are as follows 
2 h BS < 140 mg/dl = normal glucose tolerance 
2 h BS ≥ 140 mg/dl and < 200 mg/dl = impaired glucose tolerance (IGT) 
2 h BS ≥ 200 mg/dl = provisional diagnosis of diabetes (must be confirmed on 
subsequent day) 
16 
 
FBS-fasting blood sugar, 2 h BS- 2 hour post load blood sugar. 
The prognostic significance and outcome are same whether it is the FBS 
>126 mg/dl or 2 hour postprandial blood sugar >200 mg/dl(in diabetes).The 
FBG test is now mostly performed because of ease of administration , 
convenience, acceptability to patients and its lower cost. 
2-hour post load glucose is done by taking 75 g of glucose dissolved in 
300 ml of water. 
Fasting is defined as no food intake (i.e. overnight) for at least 8 hours. 
Random is defined as any time of day without regard to time since the last meal. 
Screening for diabetes:  
Diabetes is one of the diseases diagnosed late when multiple 
complications have appeared. Nearly 1/3
rd
 of group remain undiagnosed. But no 
studies have supported screening of asymptomatic persons. But use of fasting 
blood sugar as a screening test for Type 2 DM is justified in individuals at high 
risk group.  
Glycosylated haemoglobin C is also recommended for screening.  
Adverse factors for Type 2 Diabetes Mellitus
 
1. Obesity  
2. Family history of DM 
3. History of diabetes mellitus during pregnancy (GDM) or Birth of baby 
weight > 4kg   
4. HDL cholesterol level ≤ 35mg/dL or triglyceride level ≥ 250mg/dL  
17 
 
5. Race/ethnicity 
6. Type A personality  
7. Evidence of vascular disease features 
Standards of medical care in DM 
It is a chronic progressive disease that required frequent medical care for 
to decrease acute and chronic complications. 
Initial Evaluation includes 
 Detailed Medical history 
 Previous HbA1C reports.  
 Detailed history of dietary pattern, and weight history and any 
developmental delay in earlier age.  
 Detailed history of prior treatment and present treatment of DM. 
 Exercise history.   
 Previous or present infections, particularly skin, foot, oral GIT and 
urinary tract infections.   
2) Physical examination: 
 Height, weight and body mass index 
 Sexual maturation staging.  
 BP measurement, including orthostatic measurements  
 Examination of pulses  
 Oral examination.  
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 Thyroid gland examination.   
 Cardiac evaluation.  
 Eye-fundoscopic examination  
 Abdominal examination 
 Hand examination.  
 Foot examination.  
 Dermatological examination (for tinea, acanthosis nigricans and insulin-
injection sites).  
 CNS examination.  
 Examination for secondary causes of diabetes 
(e.g.hemochromatosis,pancreatic disease).  
3) Laboratory evaluation   
 HbA1C measurement 
 Fasting serum lipid profile levels, which includes total cholesterol, HDL, 
Triglycerides, LDL, VLDL. 
 Examination of micro albumin in urine in T1DM who have had duration 
of > 5 years and in all cases with T2 DM . 
 Serum creatinine.  
 Thyroid stimulating hormone (TSH) level in all T1DM, in T2DM with 
clinical features. 
 ECG in adults, if clinically needed..  
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  Examination of urine for ketone bodies, protein and sediments. 
4) Referrals: 
• Ocular examination. 
• Behavioural specialist.  
• Podiatrist.  
Goals to be achieved in Diabetes mellitus: 
HbA1C   < 7.0%  
Fasting plasma sugar: 90 – 130 mg/dl  
Post prandial plasma sugar: < 180 mg/dl  
Blood Pressure :< 130/80 mmHg 
LDL < 100 mg/dl  
Triglycerides < 150 mg/dl  
HDL> 40 mg/dl  
Blood Sugar Control Goals- An Approach : 
•Goals vary from person to person.  
•Following persons (Children, Women who have conceived and older age) need 
special care. 
•Less severe control is required in patients with recurrent episodes of 
hypoglycaemia.  
•More adequate control of blood glucose (i.e. a normal HbA1c < 6%) may 
further reduce complications. 
20 
 
•Postprandial sugar may be targeted if glycosylated haemoglobin C levels are 
not met despite reaching fasting sugar level.  
Complications of Diabetes Mellitus: 
Diabetes has both acute and chronic complications. 
Acute complications: 
It includes 
 
1.Diabetic ketoacidosis (DKA):  
 It is an acute medical emergency, characterised by 
 Increase blood sugar  
 Ketone bodies in serum and urine 
 Metabolic acidosis 
Complications: 
 Cerebral edema 
 Acute respiratory distress syndrome 
 Disseminated intra vascular coagulation 
 Thromboembolism 
 Circulatory failure 
2. Hyperglycemic Hyperosmolar state (HHS): 
It is characterised by 
 hyperglycemia without metabolic acidosis or ketone bodies  
 thromboembolic manifestations are more common 
21 
 
3. Hypoglycemia: 
 It is more common in insulin treated patients. 
4. Lactic acidosis 
 
Chronic Complications: 
1.Diabetic Retinopathy  
2.Diabetic Neuropathy  
3.Diabetic Nephropathy  
4.IHD  
5. Cerebrovascular accident 
 Transient ischemic attack, stroke 
6.Peripheral vascular disease  
 claudication, ischaemia 
7. HT  
8.Infection like Tuberculosis, Candidaisis, Mucormycosis, Necrotising fasciitis,            
Periodontitis  
9.Dupuytren's contracture  
10.Pseudogout  
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DIABETIC RETINOPATHY
12
  
It is one of the commonest cause of blindness in adults in the age group30 
to 65 years in developed countries. During the 1
st
 two decades of disease, nearly 
all patients with T1DM and >60% with T2DM have retinopathy. 21 percent of 
T2DM patients have presented with retinopathy at first visit. 
 Classification:  
Nonproliferative Diabetic Retinopathy (NPDR):  
1. Mild type: 
Presence of 1 micro aneurysm with one or more of the following :  
 Retinal haemorrhage,  
 Hard and soft exudates.  
2. Moderate type: 
 Presence of Haemorrhage/ micro aneurysms or  
 Presence of both in at least one quadrant with one or more of the 
following: 
 Soft exudates, venous beading and intra retinal microvascular 
abnormalities.  
3. Severe type: 
 Haemorrhage or micro aneurysms or  
 Both in all quadrants,  
23 
 
 Venous beading in two or more quadrants , intra retinal microvascular 
abnormalities in at least one quadrant.  
Proliferative Diabetic Retinopathy (PDR): 
1. Early: One or more of the following:  
a) NVE  
b) NVD  
c) Vitreous or preretinal haemorrhage  
d) NVE< ½ disc area.  
2. High risk: One or more of the following.  
a) NVD > ¼- 
1
/
3 
disc area  
b) NVD with vitreous or preretinal haemorrhage  
c) NVE > ½ disc area. Preretinal or vitreous haemorrhage.  
3. Advanced PDR:  
 High risk PDR, traction retinal detachment involving macula or  
 Vitreous haemorrhage obscuring ability to grade NVD or NVE.  
 IRMA – Intraretinal micro vascular abnormalities.  
 NVE – Neovascularisation elsewhere.  
 NVD – Neovascularisation over the disc 
Clinical features of Retinopathy 
 Micro aneurysms 
 Retinal haemorrhage 
24 
 
 Exudates 
 Cotton wool spots 
 Neovascularisation of retina and iris 
 Subhyaloid haemorrhage 
 Vitreous haemorrhage and fibrosis 
 Macular edema can occur at any stage of diabetic retinopathy. Non 
proliferative diabetic retinopathy usually appear at end of first decade or early 
second decade in cases of type2 diabetes mellitus. Proliferative diabetic 
retinopathy usually appears within 5 years of non proliferative diabetic 
retinopathy. Pregnancy, uncontrolled diabetes mellitus, uncontrolled HT can 
accelerate these changes.  
UKPDS study showed that strict sugar control(i.e. for every percentage of 
reduction of HbA1C) associated with  a 35% reduction in risk of retinopathy
13
,
 
and strict  BP control (to < 150/85 mmHg) results in 34% reduction
14
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Pathophysiology of microvascular complications: 
 
         Increase glucose level 
 
 
Activation of protein kinase c, Endothelial nitric oxide synthase uncoupling, 
Increase production of advanced glycation products, Activation of polyol  
      pathway 
 
 
    Activation of reactive oxygen species 
 
 
     Increase oxidative stress 
 
 
     1.Altered gene expression 
              2.Decrease nitric oxide synthesis 
             3.Activation of protein kinase C 
                                           4.Increased formation of advanced glycation 
        products 
        5.Induction of DNA damage 
                                            
26 
 
Other ocular complications : 
 Cataract 
 Glaucoma 
 Retinal detachment 
 Macular edema 
Investigations for retinopathy: 
 Visual acuity 
 Fundus examination 
 Fundus fluorescein angiography 
 Slit lamp examination 
Treatment options for retinopathy: 
 Laser photocoagulation 
 Injection of steroids 
 Anti vascular endothelial growth factor 
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DIABETIC NEPHROPATHY  
 This is most common cause of stage five chronic kidney disease in world 
wide. Compared to type2 diabetes progression to chronic kidney disease is 
higher in type1 DM.   
The diabetic nephropathy progresses from stage of microalbuminuria to 
stage of macroalbuminuria / clinical albuminuria to end stage renal disease. 
Progression from micro to macroalbuminuria usually taken upto 10-15 years.  
ESRD develops in half of T1DM patients with clinical nephropathy 
within ten years and 3/4of patients by twenty years. But in type 2 DM, even 
after twenty years of overt nephropathy only 20% progress to ESRD.  
Screening for Microalbuminuria: 
A screening test  should be done for urine microalbumin at the time of 
diagnosis in persons with T2 DM at the time of first visit , repeated after five 
years of disease duration. For patients with T1DM, test should be repeated 
yearly.  
Screening for microalbuminuria can be performed by 3 ways.  
1. Calculation of the albumin to creatinine ratio in a spot urine sample.  
2. 24 hour Urine sample and measurement of albumin excretion.  
3. Timed (e.g. 4 hr or overnight) collection.  
24 hour collection urine sample is most reliable.  
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CATEGORY 
Spot collection 
(μg/mg creatinine) 
24 Hr collection 
(mg/24 hrs) 
Timed collection 
(μg/min) 
Normal <30 <30 <20 
Microalbuminuria 30 – 299 30-299 20-199 
Macroalbuminuria ≥300 ≥300 ≥200 
 
In addition microalbuminuria is the earliest feature of renal involvement, 
it is also as a independent marker of CAD. 
  
29 
 
 
DIABETIC NEUROPATHY  
It occurs in almost half of cases with long duration of diabetes. The 
development of neuropathy is directly in correlation with the duration and 
degree of glycemic control
2,15
. 
Classification: 
 Somatic  
 Visceral or autonomic 
Somatic: 
1) Polyneuropathy 
 Symmetrical mainly sensory and motor 
 Asymmetrical mainly motor and proximal including amyotrophy 
2) Mononeuropathy including mononeuritis multiflex 
Visceral: 
 Cardiovascular 
 GIT 
 Pupillary 
 Genitourinary 
 Sudomotor 
 Vasomotor 
Possible causes of neuropathy in DM includes 
 Microangiopathy 
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 Formation of advanced glycation end products 
 Increased level of protein kinase c  
 Activation of polyol pathway leads to accumulation of sorbitol 
 
Histopathology: 
 Axonal degeneration of both myelinated and unmyelinated fibres 
 Schwann cell basal lamina hypertrophy 
 Patchy, segmental demyelination 
 Basement membrane thickening and presence of microthrombi in neural 
vessels 
 
The most common type reported is distal symmetrical sensory poly 
neuropathy. Most cases frequently presented with distal sensory loss, 
hyperesthesia, paresthesia and dysesthesia.  
Painful neuropathies may also occur. It can be an acute (lasting < 12 
months) and a chronic (lasting > 12 months).  
Individuals with long standing T1 or T2 DM are prone to develop 
autonomic diabetic neuropathy.  
Clinical features of Autonomic Neuropathy: 
Cardiovascular features 
 Orthostatic hypotension 
 Fixed heart rate 
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 Resting tachycardia 
Gastrointestinal features 
 Dysphagia 
 Nausea, vomiting, abdominal fullness 
 Constipation 
 Nocturnal diarrhoea 
Genitourinary features 
 Erectile dysfunction 
 Urinary incontinence 
 Recurrent urinary tract infections 
 Retrograde ejaculation 
Pupillary features 
 Small pupil size 
 Delayed response to light reflex 
Sudomotor features 
 Gustatory sweating 
 Increased sweating in the night 
 Anhidrosis and fissures in the feet 
Vasomotor features 
 Dependent edema 
 Bullous formation 
 Feet feel cold due to loss of vasomotor response 
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Tests for cardiovascular autonomic functions 
1) Simple reflex test 
A) Heart rate responses 
 to valsalva manoeuvre ( fifteen seconds): ratio of longest to shortest R- R 
interval Normal ≥1.21  ,abnormal≤1.20 
 to deep breathing :6 breaths over 1 minute Normal ≥15 abnormal≤10 
 to standing after lying :Ratio of  R- R interval of 30th to 15th beats Normal 
≥1.04 ,abnormal≤1 
B) Blood pressure response to standing -Systolic BP fall Normal ≤10 
abnormal≥30 
C) Special Tests 
 heart rate and BP in response to handgrip 
 heart rate and BP variability using domain analysis of ambulatory 
monitoring 
 MIBG scan of heart 
 heart rate and BP variability using power spectral analysis of ECG 
monitoring 
Diagnosis: 
 Examination of the feet  
 Look for ulceration,  
 Ankle reflexes,  
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 Tuning fork using 128-Hz shows decreased vibration perception  
 Semmes-Weinstein monofilament for pressure sensation  
 Normal results on vibration testing (Likelihood ratio range, 0.33–0.51) or 
monofilament (Likelihood ratio range, 0.09–0.54) make large fiber 
peripheral neuropathy from diabetes less likely. 
 Nerve conduction studies may show decreased conduction of the 
peripheral nerves. 
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MAGNESIUM  
Magnesium is the 4
th
 most abundant cation in the body. It is also the 2
nd
 
largest amount cation intracellularly, next to potassium. A normal adult has 21-
28gms (approximately 2000mEq) of magnesium. Nearly 60% of total body 
magnesium is present in bone, 38% is in soft tissues with slightly higher 
concentrations in liver and skeletal muscle. (15-20 mEq/Kg). and less than 2% 
is present in extracellular compartment
16
. 
Serum concentration of magnesium varies from 1.7 to 2.4 mg/dL. The 
plasma concentration in healthy adults remain remarkably constant with very 
less fluctuations due to sensitive control mechanisms that are not fully 
understood   
The mean daily oral intake of magnesium is roughly 25 mEq (140-360 
mg/day). About 40% of the dietary magnesium is absorbed in the small intestine 
mainly the ileum. Elimination is mainly through kidneys and is about 
100mg/day and it is well regulated.  So when blood levels rise more than 2.4 
mg/dl, magnesium excretion increases many folds. In event of magnesium loss 
absorption is increased dramatically, the main site being the thick ascending 
loop of Henle. Many factors inhibit reabsorption, like increased ECF volume, 
hypercalcemia, and use of thiazides.
17
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Biochemical importance of Magnesium: 
Magnesium is an activator of critical enzyme systems that maintain 
cellular metabolism. The most important being the activation of enzymes that 
hydrolyze and transfer phosphate groups in the processes involving adenosine 
triphosphate (ATP).  This ATP is essential for glucose catabolism as well as , 
lipid, amino acids, etc . 
Magnesium is a cofactor for oxidative phosphorylation inside the 
mitochondria. 
The macromolecular structure of DNA, RNA and ribosomes is 
maintained  by magnesium.
18,19 
It is also involved in protein synthesis by 
regulating the attachment of  mRNA to the 70s ribosome.
20
 
Regulation of Serum Magnesium  
A) Renal regulation: 
Renal regulation of serum magnesium concentration is mainly by altering 
its reabsorption at the thick ascending loop of Henle. Magnesium reabsorption 
is increased by parathyroid hormone and is reduced by hypercalcemia and 
hypermagnesemia 
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B) Intestinal absorption : 
Intestinal magnesium absorption mainly at jejunum and ileum is 
increased by 1,25 (OH)
2 
Vitamin D  
C) Hormonal factors23  
Increasing serum magnesium, 
 Parathyroid hormone  
 Glucagon  
 1, 25(OH)
2 
Calcitriol.  
Decreasing serum magnesium,  
 Aldosterone  
 Vasopressin (ADH)  
 Thyroxine  
 Calcitonin  
Selected Food Sources of Magnesium
22
-Magnesium content in mg/100gm) 
Nuts  
 Almonds – 315  
 Cashews – 260  
 Peanuts – 175  
 
37 
 
Legumes  
 Split Beans – 50  
  Soyabean – 86  
Fruits  
 Dates – 35  
 Banana – 30  
  Oranges – 10  
 Apple – 5  
Dairy Products  
 Milk – 24  
 Butter – 20  
 Yoghurt – 12  
Cereals  
 Shredded Wheat -110  
 Rice – 40  
Meat and fish  
 Pork – 22  
 Chicken – 21  
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 Beef – 18  
 Fish – 22  
Hypermagnesemia : 
Hypermagnesemia is very uncommon in the absence of renal 
insufficiency, kidneys can excrete huge quantities of magnesium when needed 
(up to 250 mmol/d).
24 
 
Causes of hypermagnesemia  
A) Impaired magnesium excretion  
 Renal failure  
 Familial hypocalciuric hypercalcemia  
B) Excessive magnesium intake  
 Cathartics  
 Antacid preparations  
 Parentral magnesium administration (eg.magnesium sulfate in PIH)  
C) Rapid magnesium mobilisation from soft tissues  
 Trauma  
 Extensive burns  
 Shock, sepsis  
 Post-cardiac arrest  
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D) Other disorders  
 Adrenal insufficiency  
 Hypothyroidism  
 Hypothermia  
Clinical features: 
The most important clinical presentation of hypermagnesemia are 
vasodilation and neuromuscular blockade, occurring at concentrations > 4.8 
mg/dL (>2mmol/L). Hypotension usually does not respond to intravenous fluids 
and vasopressors. 
 Lethargy and weakness may progress to respiratory failure, paralysis and 
coma with depressed deep tendon reflexes occurs at serum magnesium levels > 
4 mmol/L).  Paralytic ileus may occur. 
Prolongation of PR, QRS intervals, heart blocks and asystole occurs at 
serum magnesium levels around 10 mmol/L. 
Treatment of Hypermagnesemia: 
Generally involves recognising and removing the magnesium source 
Vigorous intravenous fluids and hemodialysis are necessary at times. 
Intravenous calcium in doses of 100-200 mg over 1 to 2 hrs provides a short 
term improvement 
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Hypomagnesemia : 
Hypomagnesemia means a significant decrease in body magnesium stores 
(0.5 to 1 mmol/Kg). . Dietary magnesium deficiency is uncommon except in 
persons consuming alcohol. 
Causes of Hypomagensemia
24
 
I.Impaired intestinal absorption  
A.Primary infantile hypomagnesemia  
B.Malabsorption syndromes  
C.Vitamin D deficiency.  
II.Increased intestinal losses  
A.Protracted vomiting / diarrhoea  
B.Intestinal drainage, fistulae  
III.Impaired renal tubular reabsorption  
A.Genetic magnesium wasting syndromes.  
1.Gitelman syndrome  
2.Bartter syndrome  
3.Na-K ATPase g-subunit mutations  
B.Acquired renal disease  
1.Tubulointerstitial disease  
2.Post obstruction /ATN (diuretic phase)  
3.Renal transplantation.  
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C.Drugs  
1.Ethanol  
2.Diuretics (loop, thiazide and osmotic)  
3.Cisplatin, cyclosporine  
4.Aminoglycosides, Amphotericin B  
IV.Metabolic causes  
1.Hyperaldosteronism  
2.SIADH 
3.Diabetes mellitus  
4.Metabolic acidosis  
5.Hypercalcemia  
6.Hyperthyroidism  
V.Others  
1.Pancreatitis  
2.Excessive sweating  
3.Osteoblastic metastases  
Many genetic/hereditary magnesium losing conditions are described , but 
are exceedingly rare. Prolonged nasogastric aspiration, intravenous fluids, 
infectious diarrhoea, fat losing enteropathies and inflammatory bowel disease 
may produce hypomagnesemia.
23 
Magnesium deficiency is quite frequent in 
patients receiving loop diuretics like Furosemide.
24
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Incidence : 
Hypomagnesemia is a relatively common electrolyte imbalance seen in 
around 12% of in- patients.
25
 .In intensive care settings incidence is very high 
(60%).Parentral nutrition, diuretic usage, decreased serum Albumin levels , and 
aminoglycosides may be responsible for this high frequency
26
 
Risk of incidence:
27 
 2% in common people.  
 10 - 20% in hospitalized patients.  
 60-70% in ICU settings. 
 30 - 80% in Alcoholics.  
 25% in diabetic patients.  
Hypomagnsemia occurs equally in males and females.  
Clinical features:
28 
The clinical features appear only when serum magnesium concentrations 
are <1.2 mg/dL (0.5 mmol/L). It is presented as irritability, Central nervous 
system hyper excitability, and arrhythmias.
29
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History : 
History concerned with hypomagensemia are usually nonspecific. They 
present with weakness, muscular cramps / palpitations. Sometimes abnormal 
behaviour  in the form of irritability, apathy, psychosis, may be seen in severe 
cases.  In few vertigo, incoordination, depression, or fits may occur. 
 
Physical signs : 
 Exaggerated deep tendon reflexes.   
 Trousseau and Chvostek sign  
 Difficulty in swallowing  due to esophageal hypomotility  
 Altered mental status  
 Ataxia, nystagmus or seizures (at levels <0.8 mg/dl) 
 Pulses may be irregular due to VPCs 
ECG : 
Hpomagnesemia can produce non specific alterations in the 
electrocardiogram.  Mild to moderate hypomagnesemia (1.2 to 1.7 mg/dl) 
producing widened QRS complexes with tall T-waves. Severe 
Hypomagnesemia (<1.2 mg/dl) produces increased PR interval,  broad QRS 
complex, flattening / T wave inversion and prominent U waves.
30
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Cardiac arrhythmias including sinus tachycardia, other supraventricular 
tachycardia and ventricular tachyarrhythmia also can occur.  
Investigations: 
Serum magnesium levels are estimated by several methods.  
 Neutron activation analysis  
 Atomic absorption spectrometry  
 Ion selective electrodes (ISE)  
 Equilibrium dialysis  
 Calmagite dye method.  
Calcium, potassium and phosphorous levels must be assessed. BUN and 
creatinine levels And Blood glucose levels should also be measured.  
Treatment of Hypomagnesemia: 
The route of magnesium replacement is according to severity of the 
clinical manifestations. Moderate to severe manifestations like patients with 
tetany or ventricular arrhythmias require 50 mEq of intravenous route slowly 
over 8 to 24 hours and repeated as and when needed to maintain concentration 
above 1.0 mg/dl.
31
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Oral replacement ( magnesium chloride & Magensium lactate) should be 
given in patients with milder presentations. The background cause should be 
corrected.  
Hypomagnesemia and   other diseases: 
A) Magnesium and cardiovascular diseases
32
  
Arrhythmias can be precipitated in hypomagnesemia especially in acute 
coronary syndrome, cardiac failure and associated hypokalemia. 
 
Torsade De pointes is a fatal arrhythmia precipitated by drugs that 
increase QT interval, electrolyte imbalance (low potassium and magnesium), or 
a decrease heart rate. Intravenous magnesium is recommended for this fatal 
condition. 
Trials show significant correlation with ischemic heart disease. decreased 
level of serum magnesium  is associated with higher incidence of ischemic heart   
disease.
39 
The underlying mechanism for the increased risk is not fully 
understood.  
Magnesium supplementation may improve the exercise tolerance, 
antithrombotic effect with aspirin and thus improves  outcome in individuals 
with ischemic heart disease.
40
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Acute MI(myocardial infarction) is often associated with significant 
reduction in serum magnesium levels.
41
Hypomagnesemia associated with acute 
MI is probably responsible for increase in the frequency of fatal arrhythmias in 
the acute period.
33
 
A positive correlation is seen in patients with hypomagnesaemia and 
CCF .It occurs due to use of diuretics. Whether this is associated with increased 
mortality is not known
.41
 
 
B) Hypertension  
Magnesium has significant role in controlling BP.
35 
 Hypomagnesemia  
leads to increased intracellular  potassium and calcium levels which leads to 
vasoconstriction and increased peripheral vascular resistance. Magnesium may 
also have   some direct effect on vascular smooth muscle.
36
 
Studies have also found that requirement of anti hypertensive dosage is 
more in patients with low serum magnesium levels. 
As per JNC recommendation high magnesium rich diet is necessary for 
prophylaxis and treatment of hypertension.
37  
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C) Stroke 
Studies have also found that increased magnesium intake decreases 
incidence of stroke.
42 
 
D) Osteoporosis 
There is a significant correlation between serum magnesium levels and 
bone mineral density.
43 
E) Asthma:  
Normal functioning of lung requires magnesium rich diet. There is a 
significant correlation between hypomagnesemia and incidence of bronchial 
asthma.  
F) Dyslipidemia 
Hypomagnesemia is associated with increased plasma LDL, 
cholesterol and triglyceride and reduced HDL.
44  
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MAGNESIUM AND DIABETES MELLITUS 
Magnesium is a essential element for metabolism of carbohydrate . 25 to 
39% diabetes mellitus patients have hypomagnesemia 
The clinical implications of magnesium deficiency in diabetes are many. 
Hypomagnesemia can be a result of hyperglycemia and can produce or increase 
insulin resistance. Hypomagnemia is implicated in the development of diabetic 
retinopathy.
 
most often higher incidence occur if associated with hypertension,
38 
thrombotic tendency,
45 
insulin resistance
46 
and the Reaven – Modan syndrome, a 
unique  clinical entity that connects diabetes mellitus, hyperinsulinemia, 
hypertension and increased thrombotic tendency – all producing  adverse 
cardiovascular outcomes.
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Causes of Hypomagnesemia in Diabetes Mellitus : 
Initially, the cause of hypomagnesemia in diabetes was supposed to be due to  
(1) Osmotic renal loss from glycosuria. 
(2) Impaired absorption from GIT .  
(3) Insulin mediated transfer of magnesium to RBC.  
Recently a specific tubular defect has been suggested which results in 
hypermagnesuria. The exact site of this defect is not yet been identified. Insulin 
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treatment has been shown to reduce magnesium losses through kidneys. 
Garland
48 
suggested that delay in insulin treatment is less effective in correcting 
the renal magnesium losses, probably due to certain irreversible changes.  
The role of magnesium in Insulin Action : 
Magnesium is a essential cofactor for insulin secretion, and activity. 
Hypomagnesemia  decreases insulin secretion by the pancreas.
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Multiple studies have shown hypomagnesemia to increase insulin 
resistance. This insulin resistance is a post receptor defect and may be 
associated with calcium mediating the signal for insulin action.
46 
 Number of 
studies have shown that tissue response to insulin is more in the presence of 
magnesium.  
In a recent study, the cellular uptake of magnesium, was shown to be 
reduced in diabetics.
50 
 there is also some proof  that low magnesium levels 
directly produces insulin resistance. Nadler et al.
56 
analysed 16 non diabetic 
individuals and found decreased insulin sensitivity after production of 
magnesium deficiency.  
Similarly elderly non diabetic individuals had improved glucose tolerance, 
when subjected to magnesium supplementations for 4 weeks.
51 
 In non diabetic 
50 
 
obese subjects, insulin resistance was found to be associated with low 
magnesium levels,  compared to non obese individuals.
52 
 
Tonyai, et al.
53 
suggested that a low erythrocyte magnesium content can 
change membrane viscosity, and impair the binding of insulin with its 
membrane. Paolisso, et al.
51 
were able to rectify the altered erythrocyte 
microviscosity with long-term magnesium supplementation.  
Role of magnesium deficiency in diabetic end organ damage:  
Magnesium deficiency is associated with diabetic microvascular disease. 
Hypomagnesemia has been shown in patients with diabetic retinopathy, with 
still lower magnesium levels in severe diabetic retinopathy.
 
Magnesium 
depletion is also related to development of diabetic polyneuropathy. Corsonello, 
et al have suggested a relationship between diabetic microalbuminuria and 
serum ionized magnesium levels. Magnesium depletion also has been associated 
with multiple macrovascular complications.
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Grafton, et al
57 
have suggested on the inositol transport theory for the 
development and progression of diabetic complications. According to this 
theory hyperglycemia leads to excessive stimulation of aldose reductase causing 
high cellular level of sorbitol. This sorbitol inhibits transport of inositol, thus 
decreasing intracellular inositol. The data of Grafton, et al show that 
51 
 
hypomagnesaemia causes a decrease in the affinity of the inositol transport 
protein for inositol, leading to a two fold reduction in rate of inositol transport 
and accelerated development of diabetic complications. 
Resnick proposed that the „primary‟ defect is the abnormal cellular ion 
handling leading to complications
47
  
There is a significant correlation between magnesium and antioxidant 
levels. Weglicki, et al have hypothesized that a fall in magnesium level leads to 
loss  of cellular activity against oxidative substances. Magnesium deficiency has 
also been shown to lower the efficiency of  substances acting againt oxidants 
such as glutathione, vitamin c and Tocopherol.  
Evidence for efficacy of Magnesium Supplementation in Diabetes Mellitus:  
There is strong evidence that repletion of magnesium can reduce the 
insulin resistance, platelet reactivity and other cardiovascular risk factors .
54
 
In a study involving 16 diabetics and 30 healthy controls, oral 
supplementation with magnesium hydroxide (250mg twice daily) resulted in 
reduced  insulin requirements in the diabetic patients. Paolisso,
51 
et al 
demonstrated  magnesium supplementation given  resulted in lower fasting 
plasma glucose levels, increased plasma magnesium levels and a  significant 
improvement in β-cell response to glucose.  
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In type 2 diabetics, oral supplementation of magnesium decreases platelet 
reactivity, and decreases the incidence of hypertension and improves lipid 
profile.
44 
 
Clinical approach to Magensium Supplementation in Diabetes Mellitus  
Diabetic patients at risk for hypomagnesemia such as ACS, DKA, chronic 
alcohol intake, prolonged duration of parentral therapy, chronic diarrhoea , 
diuretic therapy should have their magnesium levels measured.   
Overt serum hypomagnesaemia should always be corrected. If 
hypomagnesemia is clinically suspected, but not supported by serum levels, a 
further test with erythrocyte or platelet magnesium concentration is mandatory  
Magnesium chloride is the preparation of choice. Doses vary from 100 to 
600mg/day .
54 
Diarrhoea is the most important and the dose limiting side effect. 
Renal insufficiency with Glomerular filtration rate of less than 30 ml/min is the 
only factor that requires withholding dietary supplementation. 
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METHODOLOGY  
SOURCE OF DATA  
Patients with type 2 diabetes admitted in THANJAVUR MEDICAL 
COLLEGE & HOSPITAL, THANJAVUR, who satisfied the inclusion criteria 
and consented to participate in the study were included. 
PERIOD OF STUDY 
 October 2011-October 2012 
TYPE OF STUDY 
 Cross sectional study 
100 patients were randomly selected of which 50 were males and 50 were 
females. Cases with renal failure, Acute Coronary Syndromes, patients on 
diuretics, alcoholics or with malabsorption were excluded. None were taking 
magnesium supplements or magnesium containing antacids. Informed consent 
was obtained. 
INCLUSION CRITERIA  
All patients  both males and females  above 13 years of age group  with 
type 2 diabetes mellitus admitted in Internal medicine units of Thanjavur 
Medical College & Hospital, Thanjavur. 
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EXCLUSION CRITERIA  
1. Patients with chronic renal failure.  
2. Acute myocardial infarction in last 6 months.  
3. Patients on diuretics.  
4. Patients with history of alcohol abuse.  
5. Patients receiving magnesium supplements or magnesium containing 
antacids.  
6. Malabsorption or chronic diarrhea. 
7.Age<13years.  
 
DATA COLLECTION  
The 100 diabetics (50 Men & 50 Women) were included in the study. 
Detailed history – including duration of diabetes, treatment mode, symptoms 
suggestive of diabetic neuropathy, associated diseases such as hypertension and 
ischemic heart disease was obtained as per the proforma.  
Detailed physical and neurological examination was done. Retinopathy 
was assessed by direct opthalmoscopy.  
Samples were collected for estimation of fasting blood glucose and 
magnesium level. Postprandial blood sugar was measured two hours after a 
standard meal. Nerve conduction study was done on selected patients by 
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experience neurologist with symptoms & signs suggestive of neuropathy. Blood 
urea, serum creatinine and 24 hour urinary albumin were estimated. Serum 
magnesium was estimated by Calmagite dye method. HbA1C measurement 
done by a modified calorimetric method.  
CALMAGITE DYE METHOD – TEST PRINCIPLE 
Under alkaline conditions, magnesium combines with  calmagite dye to 
form a red colour which is read spectrophotometrically at 530 nm. Formation of 
colour is depends on magnesium levels.  To eliminate the interference of 
calcium during estimation, EDTA is included in the reagent. Cyanide reduces 
heavy metal interference. Surfactant reduces protein interference.  
TEST PROCEDURE  
Three test tubes labeled Blank, Standard and Test are prepared as in table. 
In test tubes  Blank  Standard  Test  
Calmagite   1 ml  1 ml  1ml  
Standard 
sample  
-  10 ml  -  
Patient‟s 
sample  
-  -  10 ml  
Distilled 
water  
10 ml  -  -  
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This test tubes are incubated at room temperature (22-28ºC). The 
absorbance of Test (A
T
), Standard (A
S
) and Blank (A
B
) are read at 530nm in 
spectrophotometer. Magnesium concentration is calculated by the following 
formula.  
Magnesium concentration (mEq/L) = (A
T
-A
B 
/ A
S
-A
B
) x 2  
Serum magnesium concentration is expressed in mg/dl by linearity of 1 
mEq/L = 1.2 mg/dl.  
According to magnesium levels patients were classified into:  
1) Normal, 1.7 to 2.4 mg/dl,  
2) Low <1.7mg/dl, 
3) High >2.4 mg/dl.  
Patients were also categorized on the basis of duration of diabetes, 
presence of ischemic heart disease or hypertension, mode of treatment, 
presence/absence of retinopathy, neuropathy and nephropathy, and glycemic 
control (FBS and HbA1C).  
Cases with diabetic retinopathy were further divided into  
a) Nonproliferative diabetic retinopathy. 
b) Proliferative diabetic retinopathy.  
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Diabetic nephropathy was graded depending on 24 hour urinary excretion of 
albumin as follows:  
No nephropathy, < 30mg/24hour. 
Microalbuminuria 30 – 299mg/24hour 
Macroalbuminuria (clinical proteinuria) >= 300 mg/24hour.  
STATISTICAL ANALYSIS 
 
The statistical analysis was done by SPSS 15 software.MS Word and 
Excel were used to generate tables and charts. Following tests were used: 
 1. Chi square test 
2. Student T test 
3. Oneway ANOVA test 
Statistical results were considered significant at P <.05 
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RESULTS 
100 cases of type 2 DM (50 males, 50 females, mean age 56.87 years) 
comprised the study group.  
Table 1: Age Distribution 
Age (in years) 
No. of Patients 
(n=100) 
Below 50yrs 30 
51 to 60yrs 41 
61 to 70yrs 22 
71yrs & above 7 
 
. 
Patients were distributed across the age spectrum of 42 to 78 years. Mean 
age 56.87 years. Most patients (n=41) were present in 51-60 group. Youngest 
patient was 42 years old.  
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Graph 1: Age Distribution
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Table 2: Characteristics of study population 
 
Characteristics  
No. of subjects  100  
Age (Years)  56.87  (42 – 78)  
Men  50 
Women  50  
Duration of diabetes 
(years)  
 8.89(2-23) 
 
Medication   
67 Oral hypoglycemics  
Insulin and oral 
hypoglycemics  
33  
  
Diet only  0 
Comorbidities   
30  Hypertension  
Ischemic heart disease  15 
Diabetic retinopathy  
NPDR  
  
33 
PDR  2  
Diabetic neuropathy  15 
Diabetic nephropathy  
Microalbumineria  
                          
29 
Macroalbumineria  4 
Poor glycemic control 39 
 
60 
 
. 
 
The average duration of diabetes in study population was   8.89 years and 
range was 2 year to 23 years. 67 patients received only oral hypoglycemic 
agents and 33 patients received both. 30 patients had hypertension and 15 
patients had ischemic heart disease and 55 patients had no comorbidities. Total 
35 patients had diabetic retinopathy. Total of 15 patients had diabetic 
neuropathy. 33 patients had Nephropathy. 
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Graph 2: Characteristics of study Population
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Table 3: Prevalence of Hypomagnesemia 
 
Sex 
Magnesium 
Statistical inference Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
Male 34 (52.3%) 16 (45.7%) X
2
=.396 
Df=1 
.529>0.05 
Not Significant 
Female 31 (47.7%) 19 (54.3%) 
 
 
 
Sl.no MG Mean S.D Statistical inference 
1 Male (n=50) .4920 .72530 T=-.622 df=98 
.536>0.05 
Not Significant 
2 Female (n=50) .5840 .75468 
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Hypomagnesemia  was found in 35 patients. 65 patients had 
normomagnesemia No patient had hypermagnesemia. No correlation was found 
between hypomagnesemia in men and women (45.7% and 54.3%% 
respectively). 
  
Graph 3: Prevalence of Hypomagnesemia
Hypomagnesemia 35%
Normomagnesemia 65%
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Table 4: Prevalence of Hypomagnesemia and duration of diabetes 
Oneway ANOVA 
 
Sl.no MG Mean S.D SS Df MS 
Statistical 
inference 
1 
Between 
Groups 
  32.917 4 8.229 
F=13.265 
.060<0.05 
Not Significant 
2 
Below 5yrs 
(n=45) 
.0000 .00000    
3 
6 to 10yrs 
(n=25) 
.8040 .78977    
4 
11 to 15yrs 
(n=15) 
1.4333 .40119    
5 
16 to 20yrs 
(n=10) 
1.2200 .64601    
6 
21yrs & above 
(n=5) 
.0000 .00000    
7 Within Groups   20.979 95 .221 
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Sl. 
no 
Duration(years) 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
1 Below 5yrs 46 (70.8%) 2 (5.7%) X
2
=4.568 
Df=4 
.067>0.05 
Not 
Significant 
2 6 to 10yrs 12 (18.5%) 13 (37.1%) 
3 11 to 15yrs 1 (1.5%) 11 (31.4%) 
4 16 to 20yrs 2 (3.1%) 8 (22.9%) 
5 21yrs & above 4 (6.2%) 1 (2.9%) 
 
  
chi-square (χ2) value is 4.568.So the correlation is insignificant p value. So, the 
duration of diabetes not significantly predict serum magnesium concentration. 
Oneway ANOVA F=13.265 in between groups also shows no significant 
correlation. The mean duration was 8.89 years (2-23).  
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Table 5: Prevalence of Hypomagnesemia and Mode of Diabetic treatment 
 
Treatment mode 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
OHA 45 (69.2%) 22 (62.9%) X
2
=.418 
Df=1 
.518>0.05 
Not 
Significant 
OHA+insulin 20 (30.8%) 13 (37.1%) 
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Table 6: Prevalence of Hypomagnesemia and Fasting blood sugar 
 
Sl.No FBS 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
1 Below 90 8 (12.3%) 2 (5.7%) 
X
2
=45.582 
Df=5 
.000<0.05 
Significant 
2 91 to 100 11 (16.9%) 0 
3 
101 to 
110 
10 (15.4%) 9 (25.7%) 
4 
111 to 
120 
19 (29.2%) 1 (2.9%) 
5 
121 to 
130 
13 (20%) 2 (5.7%) 
6 
131 & 
above 
4 (6.2%) 21 (60%) 
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Prevalence of hypomagnesemia is high when fasting blood sugar 
>131(60%). The chi-square (χ2) value is 45.582. So the correlation is significant. 
So, fasting blood sugar can significantly predict serum magnesium 
concentration. 
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Table 7: Prevalence of Hypomagnesemia and HbA1c 
Sl.no HbA1C 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
1 Below 6 8 (12.3%) 2 (5.7%) 
X
2
=10.408 
Df=5 
.064>0.05 
Not Significant 
2 6 to 7 18 (27.7%) 5 (14.3%) 
3 7 to 8 15 (23.1%) 5 (14.3%) 
4 8 to 9 5 (7.7%) 9 (25.7%) 
5 9 to 10 8 (12.3%) 4 (11.4%) 
6 
10 & 
above 
11 (16.9%) 10 (28.6%) 
 
 
 
 
 
 
 
 
Serum magnesium concentration showed no significant association with 
HbA1C. Chi square X
2
=10.408,Df=5 P value .064 . Higher prevalance of 
hypomagnesemia observed in HbA1c > 10 (28.6%). 
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Table 8: Prevalence of Hypomagnesemia and Diabetic Retinopathy 
 
Particulars 
No.of Patients 
(n=100) 
Percentage 
(100%) 
No Retinopathy 65 65.0 
NPDR 33 33.0 
PDR 2 2.0 
 
 
 
Sl.no Retinopathy 
Magnesium 
Statistical 
inference 
Normomagnesemia  
(n=18) 
hypomagnesemia  
(n=17) 
1 NPDR 18 (100%) 15 (88.2%) X
2
=4.746 
Df=1 
.034<0.05 
Significant 
2 PDR 0 2 (11.8%) 
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Observations revealed a definite correlation between hypomagnesemia 
and diabetic retinopathy. The chi-square (χ2) value is 4.746. Df=1 .p value is 
0.034.  
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TABLE.9: Prevalence of Hypomagnesemia and Diabetic Neuropathy 
 
Particulars 
No. of patients 
(n=100) 
Percentage 
(100%) 
No neuropathy 85 85.0 
neuropathy 15 15.0 
 
Sl.no Neuropathy 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia  
(n=35) 
1 Negative  60 (92.3%) 25 (71.4%) X
2
=7.778 
Df=1 
.005<0.05 
Significant 
2 Positive 5 (7.7%) 10 (28.6%) 
 
Observations revealed a definite correlation between hypomagnesemia 
and diabetic neuropathy. The chi-square (χ2) value is 7.778. Df=1 .p value is 
0.005. 
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Table 10: Prevalence of Hypomagnesemia and Diabetic Nephropathy 
Particulars 
No.of persons 
(n=100) 
Percentage 
(100%) 
No albumminuria 67 67.0 
Macroalbuminuria 4 4.0 
Microalbuminuria 29 29.0 
 
 
 
 
 
Sl. 
no 
Nephropathy 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
1 No albuminuria 65 (100%) 2 (5.7%) X
2
=91.471 
Df=2 
.000<0.05 
Significant 
2 Macroalbuminuria 0 4 (11.4%) 
3 Microalbuminuria 0 29 (82.9%) 
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Observations revealed a definite correlation between hypomagnesemia 
and diabetic nephropathy. The chi-square (χ2) value is 91.471. Df=2 .  
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Table 11: Prevalence of Hypomagnesemia and Ischemic Heart Disease 
 
Sl.no IHD 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
1 Absent 54 (83.1%) 31 (88.6%) X
2
=.539 
Df=1 
.463>0.05 
Not Significant 
2 Present 11 (16.9%) 4 (11.4%) 
 
Serum magnesium concentration showed no significant relation with ischemic 
heart disease, X
2
=.539,Df=1.P value is insignificant. 
. 
. 
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Table 12: Prevalence of Hypomagnesemia and Hypertension 
 
Sl.no SHT 
Magnesium 
Statistical 
inference 
Normomagnesemia 
(n=65) 
Hypomagnesemia 
(n=35) 
1 Absent  43 (66.2%) 27 (77.1%) X
2
=1.308 
Df=1 
.253>0.05 
Not Significant 
2 Present 22 (33.8%) 8 (22.9%) 
 
 
Serum magnesium concentration showed no significant with systemic 
hypertension, X
2
=1.308,Df=1.P value is insignificant 
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Table 13: Distribution of Complications 
 
 
COMPLICATIONS 
Hypomagnesemia 
(no=35) 
Normomagnesemia 
(no=65) 
IHD 
 
4(11.4%) 11(16.9%) 
HTN 
 
8(22.9%) 22(33.8%) 
RETINOPATHY 
 
35(48.6%) 18(27.7%) 
NEUROPATHY 
 
10(28.6%) 5(7.7%) 
NEPHROPATHY 
 
33(94.3%) 0 
FBS 131 & ABOVE 
 
21(60%) 4(6.2%) 
. 
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Among the persons with low serum magneseum level prevalence rates of 
IHD , HTN, Diabetic neuropathy, Diabetic nephropathy,Diabetic Retinopathy 
and Fasting glucose levels were compared to normomagnesemic group. Study 
shows increased incidence of Diabetic neuropathy, Diabetic nephropathy, 
Diabetic Retinopathy in hypomagnesemic patients compared to 
normomagnesemics. 
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DISCUSSION 
Reports of increase prevalence of low plasma magnesium concentrations 
among diabetic patients and possible association of hypomagnesemia with 
diabetic complications prompted this study.  
Marked magnesium deficiency has been reported in the previous case 
series of type-2 DM.
 
However, some workers have also reported normal and 
even high levels.
58 
The present study, shows serum magnesium level of 35 cases 
with type 2 DM,  below the reference range. This confirms to the reported 
prevalence of low plasma magnesium status in T2DM in several studies, which 
ranged from 13.5% to 47.7%. Prevalence of hypomagnesemia in T2 DM in our 
study was similar to that reported by Nadler et al.
56 
Walti MK et al.
60 
also 
reported a 37.6% prevalence of hypomagnesemia in T2DM  versus 10.9% in 
nondiabetic controls in  Zurich, Switzerland.  
Serum magnesium concentration though less sensitive, is a highly 
specific indicator of low magnesium status.  
Low dietary intake is an unlikely cause of impaired magnesium status in 
diabetes. A dietary assessment conducted in Europe showed that only 5.4 
percentage of the diabetics and 9.1perccentage of the control group had  
magnesium intake less than reference range .
 
In addition, recently it has been 
shown that controlled diabetics have absorption of magnesium to a similar as 
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healthy controls. Increased urinary magnesium excretion due to hyperglycemia 
and osmotic diuresis may contribute to hypomagnesemia in diabetes.  
Serum levels of magnesium have been found by several investigators to 
correlate inversely with fasting blood glucose concentration
 
and the percentage 
of HbA1C.
 
Schlienger et al.
59 
hypothesized that patients with uncontrolled 
diabetics showed low serum magnesium concentration. The present study also 
revealed statistically significant correlation between serum magnesium levels 
and fasting blood sugar ( Prevalence of hypomagnesemia  high in fasting blood 
sugar value above 131 mgs% is 60% ) but  there is no significant correlation 
with HbA1C. However a higher prevalance of hypomagnesemia is observed in 
HbA1c > 10 (28.6%) in the present study. 
Hypomagnesemia is reported to be both a cause and result of poor 
glycemic control. Magnesium is necessary for glucose entry into the cell and act 
as a cofactor for enzymes of carbohydrate metabolism. In addition, magnesium 
deficiency has been shown to promote insulin resistance in multiple studies. 
Nadler et al.
56 
have reported that insulin sensitivity decreases even in 
nondiabetics individuals after induction of magnesium deficiency. Likewise, 
elderly subjects were shown to have improved glucose tolerance when they 
received magnesium supplements. Thus hypomagnesemia by itself results in 
poor glycemic control.  
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Conversely, hyperglycemia and osmotic diuresis may lead to increased 
urinary magnesium excretion and hypomagnesemia in diabetics. However, high 
prevalence of hypomagnesemia is reported in type – 2 diabetics with good 
glycemic control.
 
So, although poor glycemic control is associated with 
magnesium deficiency, it is not simply induced by hyperglycemia and is not 
corrected by improvement in metabolic control alone. 
Sex, age duration of diabetes were not the significant predictors of serum 
magnesium levels. Yajnick et al.
58 
in 1984 reported that among patients with 
DM serum magnesium levels depends on age and males had  higher serum 
magnesium levels than females. The increasing magnesium levels with age 
were probably due to impaired renal function and the sample size, (87 diabetics, 
30 non diabetics) was relatively small to confirm male preponderance. In our 
study, patients with impaired renal functions were excluded. Our results confirm 
to the recent reports that have not shown any significant associations between 
sex, age and duration of diabetes with serum magnesium levels.
61 
Significant differences, in serum magnesium concentrations have been 
reported between the insulin treated and non-insulin treated diabetics. In our 
study revealed prevalence of hypomagnesemia is low in insulin treated patients 
compared to non insulin treated patients. ((37.1% v/s 62.9%) . Yajnik et al.
58 
reported that insulin treated diabetics have significantly lower serum 
magnesium levels compared to non insulin treated ones. However, the 
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difference was statistically not significant. Walti MK et al
61 
have reported that 
diabetes treatment (insulin or OHA) did not significantly predict 
hypomagnesemia. Insulin mediates entry of magnesium from plasma to RBC. In 
a recent study Alzaida et al.
50 
have found that cellular uptake of magnesium is 
normally stimulated by insulin. So insulin treatment may enhance cellular 
magnesium uptake and result in increased prevalence of hypomagnesemia.  
In our study, no association was found between incidence of ischemic 
heart disease and hypomagnesemia. However, several observational studies 
have reported hypomagnesemia is associated with higher risk of ischemic heart 
disease. As part of Atherosclerosis risk in communities study, a cohort of 
15,792 subjects were studied over 7 years and an increasing relative risk of 
coronary artery disease with decreasing serum magnesium was reported.
39 
How 
a low serum magnesium predisposes to coronary artery diseases is not identified 
yet. However, in our study, no difference in prevalence of hypomagnesemia was 
found between those with ischemic heart disease and others. Similarly, no 
difference in prevalence of hypomagnesemia was found between the 
hypertensive and non hypertensive subjects.  
Trails have shown that magnesium deficiency has been associated with 
diabetic microvascular disease. In our study increased prevalence of 
hypomagnesemia was observed in diabetics with microvascular complications 
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and mean serum concentration of magnesium in diabetics with microvascular 
complications was comparatively lower than in diabetics with no microvascular 
complications.  
Hypomagnesemia has been reported in patients with diabetic retinopathy, 
with lower magnesium levels predicting a greater risk of severe diabetic 
retinopathy.
 
Our observations revealed a definite association between diabetic 
retinopathy and lower serum magnesium levels. There was a significant 
difference is prevalence of hypomagnesemia in diabetics with retinopathy and 
without retinopathy (48.6% Vs 27.7%; P< 0.005). These observations are 
similar to other reports. Grafton et al.
57
 
have proposed the inositol transport 
theory to explain this association. But the exact reason remains obscure.  
Hypomagnesemia is seen in cases with diabetic neuropathy, with lower 
magnesium levels predicting a greater risk of severe diabetic neuropathy. The 
present study revealed patients with diabetic neuropathy had a slightly higher 
prevalence of hypomagnesemia compared to those without neuropathy (28.6% 
v/s 7.7%). Rodriguez- Moran and Guerrero-Romero hypothesized that low 
serum magnesium level causes high incidence of diabetic foot ulcers. .   
Hypomagnesemia is seen in cases with diabetic nephropathy. Decreased 
magnesium levels predicts a increased risk of severe diabetic nephropathy. The 
present study shows patients with diabetic nephropathy had a slightly increased 
incidence of hypomagnesemia than in those without nephropathy(94.3% v/s 
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0%). Corsonello, et al demonstrated decreased serum magnesium in type 2DM 
with nephropathy compared to normal patients.  Recent study, shows that 
decreased magnesium concentration is associated with rapid loss of renal 
function in patients with type 2DM. 
In summary, the present study has demonstrated that hypomagnesemia is 
common in type2 diabetics and magnesium deficiency is conclusively 
associated with diabetic retinopathy, neuropathy, nephropathy.  
Diabetic patients need regular monitoring of serum magnesium 
concentration. If low level is reported magnesium supplementation is necessary. 
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CONCLUSION 
1) Prevalence of hypomagnesemia in type2 Diabetics is 35%. 
2) Prevalence of hypomagnesemia is higher in Patients with microvascular 
diabetic complications than in those without microvascular 
complications.  
3) Hypomagnesemia is significantly associated with retinopathy, 
neuropathy and nephropathy.  
4) No significant association was seen with ischemic heart disease and 
Hypomagnesemia. 
5)  No significant association was seen with Hypertension and 
Hypomagnesemia. 
6) Prevalence of hypomagnesemia was high in patients with fasting blood 
sugar >131mg/dl.   
7) No significant differences were seen among both sexes. 
8) No significant association of hypomagnesemia were seen  with duration 
of diabetes and HbA1c levels. 
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SUMMARY 
Present study was conducted to estimate the prevalence of 
hypomagnesaemia in type 2 diabetics and to study the possible association of 
hypomagnesaemia with diabetic complications and comorbidities. 
The study included 100 type 2 diabetic cases, with no factors significantly 
altering the serum magnesium levels. Fasting serum magnesium levels were 
estimated and correlation was done with variable parameters. 
The results found that prevalence of low magnesium levels(<1.7 mg/dl) 
in type 2 diabetic cases were 35% and magnesium deficiency was significantly 
associated with diabetic retinopathy, neuropathy and nephropathy . No 
significant correlation was identified with other parameters – IHD, hypertension, 
duration of diabetes and treatment modality. Causes of hypomagnesemia are 
multifactorial. Because available data suggests that low magnesium levels 
associated with adverse clinical outcomes. So it is prudent in clinical practice to 
periodically monitor plasma magnesium concentrations in diabetic patients and 
the condition corrected whenever possible. 
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 ANNEXURE I- ABBREVIATIONS 
T1 and T2DM    ─Typy1 and type2 Diabetes Mellitus 
HTN                        ─ Systemic Hypertension 
CAD/IHD    ─ Coronary Artery Disease/ 
         Ischemic Heart Disease 
CVA     ─ Cerebrovascular Disease 
FPG/FBS    ─ Fasting Plasma Glucose/ 
         fasting blood sugar 
PPPG/PPBS    ─ Post Prandial Plasma Glucose/ 
         Post Prandial Blood sugar. 
HDL     ─ High Density Lipoprotein 
VLDL    ─Very low Density Lipoprotein 
ECG     ─ Electrocardiogram 
IGT      ─ Impaired Glucose Tolerance  
HbA1C     ─ Glycosylated Haemoglobin 
IFG     ─ Impaired Fasting Glucose  
OGTT    ─ Oral Glucose Tolerance Test 
  
 ANNEXURE II – PROFORMA  
Serial No. :  
Patient Details  
Name :  
Hospital No. :  
Age :  
Sex :  
Occupation :  
Diabetic History  
Age of onset :  
Total Duration :  
Mode of Treatment  
1. Oral hypoglycemic agents :   
2. Insulin (Type) :  
3. Diabetic Diet :  
Symptoms Related to Complications  
A) Symptoms of Neuropathy  
• Postural dizziness :  
• Weakness :  
• Numbness/parasthesia :  
• Pain/hyperaesthesia :  
 • Bladder incontinence :  
• Impotence :  
B) Symptoms of Nephropathy  
• Oliguria :  
• Oedema :  
C) Symptoms of Retinopathy  
• Dimness of vision :  
• Blindness :  
Past History  
• IHD :                                  • HTN :  
Family History  
• DM :  
• IHD :  
• HTN :  
Examination  
Height :  Weight :  
General Examination:  
Pulse Rate:   Icterus :  Cyanosis:   Clubbing:  Lymph Nodes: 
Edema:  
BP: Supine:   Standing:  
A. Sensory motor Neuropathy  
• Loss of pain and temperature sense :  
 • Loss of touch :  
• Loss of position and vibration sense :  
• Rhomberg test :  
B. Proximal Muscle Neuropathy  
• Wasting :  
• Power :  
• Tone :  
• Knee jerk :  
• Ankle jerk :  
C. Eye Signs  
• Diabetic retinopathy :  
o Non Proliferative :  
o Proliferative :  
D. Signs of nephropathy  
• Oedema :  
• Facial puffiness :  
E. Cardiovascular system  
F. Respiratory system  
G. Abdomen 
Investigations  
      1. FBS:   PPBS:   HbA1C :  
2. Serum Magnesium:  
 3. 24 hour albuminuria:  
4. Urea:   Creatinine:  
5. Routine Urine:  
Sugar:   Protein :   Microscopy:  
6 ECG:  
7 Nerve conduction study: 
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1 Sundarraj 2153 50 m 46 4 oha A A A A A 90 130 5.8 2 
2 Balasubramanian 2168 58 m 48 10 oha+insulin A A NPDR A Microalbuminuria 102 145 6.6 1.5 
3 Rajendran 2169 56 m 46 10 oha+insulin A P NPDR P Microalbuminuria 155 160 11.1 1.6 
4 Jothiraman 2175 65 m 53 12 oha A P pdr A Microalbuminuria 120 180 8 1.5 
5 Rajamanikam 2201 65 m 54 11 oha P P NPDR P Microalbuminuria 105 145 5.4 1.4 
6 Samivel 2198 60 m 56 14 oha+insulin A P NPDR P Microalbuminuria 145 166 7.8 1.6 
7 Sekar 2196 55 m 45 10 oha A A NPDR A Microalbuminuria 102 170 9.6 1.5 
8 Govindaraj 2211 78 m 56 22 oha+insulin A A NPDR P A 112 184 8.8 2.1 
9 Singaram 2214 75 m 54 21 oha A A A P A 120 175 5.8 2.2 
10 Ramalingam 2217 62 m 48 14 oha A A A P Microalbuminuria 155 196 6.6 1.6 
11 Devendran 26234 42 m 40 2 oha A A A A A 100 185 8.5 2.4 
12 Johnson 26239 45 m 42 3 oha A A A A A 80 130 6.8 2.2 
13 Kandasamy 2756 78 m 56 22 oha+insulin P P NPDR P A 120 155 9.8 2.1 
14 Visvalingam 2757 53 m 49 4 oha A A A A A 102 154 8.6 2.4 
15 Selvaraj 2750 57 m 47 10 oha+insulin A A NPDR A Microalbuminuria 145 190 5.4 1.6 
16 Pandiyan 2754 70 m 52 18 oha+insulin P P NPDR A A 112 165 10.6 2.2 
17 Ravi 2357 45 m 41 4 oha A A A A A 100 155 6.8 2.1 
18 Mahalingam 2359 55 m 51 4 oha A A A A A 140 200 9.8 2.2 
19 Narayanasamy 2461 63 m 53 10 oha A A pdr A Microalbuminuria 106 170 8.5 1.5 
20 Ramasamy 2462 45 m 42 3 oha A A A A A 112 146 10.5 2.2 
21 Subramanyam 2463 51 m 47 4 oha A A A A A 80 130 5.4 2.4 
22 Paulraj 2468 50 m 45 5 oha+insulin A P A A A 102 172 7.8 2.4 
23 Ayyamperumal 2470 45 m 42 3 oha A A A A A 90 165 5.5 2.2 
24 Kalilahamed 2472 51 m 48 3 oha A P A A A 120 188 7.6 2.4 
25 Sekar 2664 50 m 46 4 oha A P A A A 95 165 6.4 2.4 
26 murugesan 2665 50 m 48 2 oha A A A A A 122 174 10.4 2.2 
27 mahalingam 2668 65 m 51 14 oha+insulin A A A P Microalbuminuria 106 166 7.6 1.6 
28 srinivasan 2659 45 m 40 5 oha+insulin A A A A A 122 200 10.8 2.4 
29 valathan 2892 50 m 46 4 oha A P A A A 96 160 6.5 2.4 
30 ramalingam 2894 60 m 46 14 oha A A A A A 160 200 9.6 1.5 
31 mahalingam 2888 42 m 40 2 oha A A A A A 112 180 6.4 2.3 
32 thangaraj 2885 71 m 53 18 oha A A A A Microalbuminuria 140 186 8.5 1.6 
33 jayamani 2877 55 m 45 10 oha+insulin A A NPDR A A 122 202 11 2.3 
34 dachianamoorthi 2881 50 m 47 3 oha A A A A A 102 160 6.4 2.3 
35 manivel 2878 55 m 46 9 oha P P NPDR A A 118 146 7.4 2.4 
36 nagarajan 2921 70 m 52 18 oha A A NPDR A Microalbuminuria 90 166 8.8 1.5 
37 natarajan 2911 65 m 51 14 oha+insulin A A A A Microalbuminuria 152 190 9.4 1.5 
38 kumarasamy 2919 55 m 50 5 oha A A A A A 110 164 9.4 2.4 
39 nagarajan 2910 57 m 48 9 oha P P NPDR A A 122 153 6.4 2.2 
40 saminathan 2912 50 m 47 3 oha A A A A A 115 142 7.6 2.2 
41 subramanyam 2840 60 m 45 15 oha+insulin A A NPDR A Microalbuminuria 140 204 6.6 1.6 
42 murugesan 2317 48 m 46 2 oha A A A A A 112 174 10.8 2.2 
43 narayanan 2320 65 m 55 10 oha+insulin A P A A A 122 190 6.8 2.4 
44 ponnaiyapillai 2321 51 m 46 4 oha A P A A A 105 168 7.6 2.4 
45 sarangabani 2327 60 m 45 15 oha A A A A A 150 190 9.8 1.5 
46 govindan 2500 78 m 56 22 oha+insulin A A NPDR A A 115 155 11.4 2.3 
47 govindaraj 4084 70 m 54 16 oha+insulin A A NPDR A A 136 162 6.4 2.3 
48 gunasekaran 4730 48 m 45 3 oha A A A A A 105 156 11.1 2.4 
49 devendaran 3993 42 m 40 2 oha A P A A A 118 146 7.5 2.2 
50 sundarraj 2347 52 m 47 5 oha A A A A A 80 155 5.4 2.3 
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51 banumathi 2156 52 f 49 3 oha A A A A A 126 170 7.6 2.2 
52 vijayanthimala 2163 45 f 43 2 oha A A A A A 95 130 6.8 2.4 
53 neelavathi 2165 60 f 51 9 oha+insulin P P NPDR A A 126 176 5.6 2.4 
54 mariammal 2166 55 f 46 9 oha+insulin A A NPDR A A 110 146 7.4 2.4 
55 pitchaiammal 2173 60 f 46 14 oha+insulin A A A A Microalbuminuria 140 190 8.4 1.5 
56 rengammal 2184 50 f 46 4 oha A A A A A 155 174 6.8 2.3 
57 mariammal 2185 60 f 46 14 oha A A A A Microalbuminuria 90 145 10.6 1.6 
58 ramamirtham 2190 61 f 46 15 oha P P NPDR A A 130 180 6.6 2.3 
59 visalatchi 2219 64 f 49 15 oha+insulin A A NPDR A Microalbuminuria 155 210 10.4 1.6 
60 panchavarnam 2230 65 f 50 15 oha A A NPDR A Macroalbuminuria 126 186 7.4 1.5 
61 muthulakshmi 2238 55 f 47 8 oha+insulin P P NPDR A A 105 146 9.5 2.3 
62 jayashanthi 2240 48 f 45 3 oha A A A A A 130 174 11 2.4 
63 anjalai 2262 55 f 50 5 oha A A A A A 115 146 6.2 2.2 
64 sundaravadhini 2263 52 f 48 4 oha A A A A A 95 156 10.5 2.4 
65 rathinammal 2278 60 f 51 9 oha+insulin P P NPDR A A 126 172 7.8 2.3 
66 tharasa 2268 50 f 46 4 oha A A A A A 106 165 9.4 2.4 
67 gowri 2307 70 f 60 10 oha+insulin A P A P Microalbuminuria 146 189 10.5 1.6 
68 meri 2335 63 f 46 17 oha A P A P Macroalbuminuria 155 208 8.8 1.5 
69 muniammal 2338 68 f 52 16 oha+insulin P P A P Microalbuminuria 105 145 10.8 1.6 
70 ambiga 2342 63 f 53 10 oha A P A P Microalbuminuria 150 204 6.6 1.6 
71 manoranjitham 2354 50 f 47 3 oha A A A A A 118 165 7.5 2.2 
72 mamta beevi 2360 62 f 43 19 oha A A A A Microalbuminuria 140 175 11.6 1.5 
73 shanta 2473 55 f 52 3 oha A A A A A 96 155 6.4 2.2 
74 indirani 2507 50 f 46 4 oha A P A A A 135 160 7.4 2.2 
75 chinnamani 2521 70 f 54 16 oha A A A A Microalbuminuria 110 170 11.4 1.6 
76 saroja 2530 65 f 47 18 oha P A NPDR A Microalbuminuria 145 190 8.6 1.4 
77 vairam 2540 65 f 49 16 oha P A A A Macroalbuminuria 126 176 10.8 1.5 
78 shanhakumari 2550 45 f 41 4 oha A A A A A 98 140 10.6 2.2 
79 rani 2555 45 f 43 2 oha A P A A A 130 184 6.4 2.3 
80 amaravathi 2554 60 f 50 10 oha+insulin A A A A Microalbuminuria 160 205 8.4 1.6 
81 tamilselvi 2867 55 f 47 8 oha+insulin A A NPDR A A 130 166 9.6 2.4 
82 rajathi 2572 44 f 42 2 oha A P A A A 90 145 7.7 2.4 
83 mariyayi 2595 43 f 41 2 oha A A A A A 98 160 8.6 2.4 
 
84 
dhanalakshmi 2624
3 
73 f 50 23 oha+insulin P A NPDR P A 130 174 6.5 2.4 
85 anjalai 2624
5 
55 f 47 8 oha+insulin P A NPDR P A 118 186 9.4 2.3 
86 arokiyameri 2623
7 
60 f 50 10 oha+insulin A A NPDR A Microalbuminuria 110 185 10.6 1.5 
87 jayaseeli 2624
0 
75 f 65 10 oha A A NPDR P Microalbuminuria 138 202 6.6 1.6 
88 malarvizhi 2645 52 f 47 5 Oha A A A A A 115 165 7.4 2.3 
89 saroja 2667 58 f 48 10 oha+insulin P A NPDR A A 106 144 6.4 2.4 
90 pappa 2666 59 f 49 10 Oha A A A A Macroalbuminuria 145 180 8.4 1.5 
91 sebastiammal 2694 50 f 46 4 Oha A A A A A 90 145 7.6 2.4 
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92 
chellammal 2696 55 f 50 5 oha+insulin A A NPDR A A 118 147 6.8 2.3 
93 
ranjitham 2691 60 f 50 10 oha A A NPDR A Microalbuminuria 155 180 11.2 1.4 
94 
dhanalakshmi 2700 47 f 44 3 oha A P A A A 95 165 5.6 2.3 
95 
chellammal 3902 55 f 50 5 oha+insulin A P A A A 115 145 8.6 2.3 
96 
vatchala 4223 62 f 52 10 oha A A NPDR A Microalbuminuria 140 180 7.4 1.6 
97 
ambigabathi 2707 58 f 50 8 oha A P A A A 120 176 9.6 2.3 
98 
malarkodi 2708 60 f 45 15 oha A A A A Microalbuminuria 110 190 8.8 1.5 
99 
saratha 2709 50 f 46 4 oha A A A A A 100 173 7.6 2.4 
10
0 
padmavathi 2713 55 f 50 5 oha+insulin A P A A A 90 155 5.4 2.4 
 
 
  
 ANNEXURE IV – KEYS TO MASTER CHART 
A- Absent 
F - Female  
FBS - Fasting Blood Sugar  
HbA1C - Glycosylated Hemoglobin  
HTN - Hypertension  
IHD - Ischemic Heart Disease  
M - Male  
Mg - Serum magnesium concentration  
NPDR - Non Proliferative diabetic retinopathy  
OHA - Oral Hypoglycemic Agent  
PDR - Proliferative diabetic retinopathy  
  PPBS - Post Prandial Blood Sugar 
  P         - Present 
 
 
 ANNEXUREV-PATIENT CONSENT FORM 
 
Study detail  : “STUDY OF SERUM MAGNESIUM LEVEL IN TYPE 2 
         DIABETES MELLITUS” 
Study centre  :   THANJAVUR MEDICAL COLLEGE & HOSPITAL 
 
Patients Name  : 
Patients Age  : 
Identification Number: 
    
 Patient may check (     ) these boxes 
I   confirm that I have understood the purpose of procedure for the above study.  
I have the opportunity to ask question and all my questions and doubts have  
been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free  
to withdraw at any time without giving reason, without my legal rights being  
affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s  
behalf, the ethical committee and the regulatory authorities will not need  
my permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the study I 
agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I agree 
not to restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions  
given during the study and faithfully cooperate with the study team and  
to immediately inform the study staff if I suffer from any deterioration in my health or 
well being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby  give permission to undergo complete clinical examination and  
diagnostic tests including haematological, biochemical, radiological tests. 
 
 
Signature/thumb impression:    
Patients Name and Address:                           Place   Date 
 
Signature of investigator :    
Study investigator’s Name :                               Place   Date    
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